Given that CD44+CD117+ cells derived from the 2008 ovarian cancer cell line possess all CSC properties18, this result suggests that the ALDH1A1 inhibitor is also able to inhibit the ovarian cancer cell dedifferentiation. Here, CD44 is linked to ovarian carcinoma.